Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EXEL
stocks logo

EXEL

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
574.36M
-9.86%
--
--
592.78M
+9.87%
--
--
608.94M
+7.44%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Exelixis, Inc. (EXEL) for FY2025, with the revenue forecasts being adjusted by 3.6% over the past three months. During the same period, the stock price has changed by 7.03%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.6%
In Past 3 Month
Stock Price
Go Up
up Image
+7.03%
In Past 3 Month
16 Analyst Rating
up Image0
Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 42.21 USD with a low forecast of 29.00 USD and a high forecast of 56.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
6 Hold
0 Sell
Moderate Buy
up Image0
Current: 40.370
sliders
Low
29.00
Averages
42.21
High
56.00
up Image0
Current: 40.370
sliders
Low
29.00
Averages
42.21
High
56.00
H.C. Wainwright
Buy
maintain
$40 -> $47
2025-06-12
Reason
H.C. Wainwright
Price Target
$40 -> $47
2025-06-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Exelixis to $47 from $40 and keeps a Buy rating on the shares. The company presented dose expansion results for zanzalitinib in first-line clear cell renal cell carcinoma, the most common type of kidney cancer in adults, the analyst tells investors in a research note. The firm says zanzalintinib plus Opdivo achieved a 63% confirmed overall response rate, with a median progression-free survival of 18.5 months. H.C. Wainwright increased its probability of approval for zanzalitinib in clear cell renal cell carcinoma to 60% from 50%.
BofA
Neutral
maintain
$45 -> $46
2025-06-05
Reason
BofA
Price Target
$45 -> $46
2025-06-05
maintain
Neutral
Reason
BofA raised the firm's price target on Exelixis to $46 from $45 and keeps a Neutral rating on the shares. Exelixis' zanza pipeline asset is increasingly important to the stock and entering a critical juncture in terms of readouts, the analyst tells investors in a research note. The Phase 3 colorectal cancer readout is the most consequential as bull-case outcomes could start to narrow the gap between zanza's de-risked peak sales and current Cabo levels, the firm says.
Citi
Buy
upgrade
$45 -> $56
2025-05-15
Reason
Citi
Price Target
$45 -> $56
2025-05-15
upgrade
Buy
Reason
Citi raised the firm's price target on Exelixis to $56 from $45 and keeps a Buy rating on the shares. The company reported a strong start to the year with total revenue of $555M that easily exceeded consensus by over 12%, the analyst tells investors in a research note. The firm says Exelixis' follow-on asset zanzalintinib "will have a flurry" of Phase 3 topline readouts in major solid tumor indications in 2025 that could further invigorate sales growth for the company.
Guggenheim
Michael Schmidt
Buy
maintain
$42 -> $45
2025-05-15
Reason
Guggenheim
Michael Schmidt
Price Target
$42 -> $45
2025-05-15
maintain
Buy
Reason
Guggenheim analyst Michael Schmidt raised the firm's price target on Exelixis to $45 from $42 and keeps a Buy rating on the shares, citing increased FY25 revenue guidance and the firm's revised estimates for Cabometyx following "an impressive net product revenues beat" in Q1.
Citizens JMP
Outperform
maintain
$41 -> $46
2025-05-14
Reason
Citizens JMP
Price Target
$41 -> $46
2025-05-14
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Exelixis to $46 from $41 and keeps an Outperform rating on the shares. Cabozantinib significantly surpassed consensus sales due to Q1 dynamics, and was also well above the firm's higher-than-consensus estimate, the analyst tells investors in a research note. The firm is encouraged by the strong reacceleration in renal cell carcinoma, where cabo continues to gain market share.
Stifel
Hold
maintain
$36 -> $38
2025-05-14
Reason
Stifel
Price Target
$36 -> $38
2025-05-14
maintain
Hold
Reason
Stifel raised the firm's price target on Exelixis to $38 from $36 and keeps a Hold rating on the shares. Cabometyx sales of $511M "easily beat" the firm's and consensus estimates, notes the analyst, whose updated model mostly reflects higher FY25 estimates and the NET launch, which the firm says should prove a tailwind to FY25 top-line growth and command an additional guidance raise above the $100M announced already.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Exelixis Inc (EXEL.O) is 18.41, compared to its 5-year average forward P/E of 33.22. For a more detailed relative valuation and DCF analysis to assess Exelixis Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
33.22
Current PE
18.41
Overvalued PE
51.62
Undervalued PE
14.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
19.45
Current EV/EBITDA
11.84
Overvalued EV/EBITDA
30.63
Undervalued EV/EBITDA
8.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
4.17
Current PS
4.92
Overvalued PS
5.30
Undervalued PS
3.04

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

EXEL News & Events

Events Timeline

(ET)
2025-06-20
06:57:16
Exelixis says Ipsen receives positive CHMP opinion for Cabometyx
select
2025-05-22 (ET)
2025-05-22
17:34:10
Exelixis announces results from expansion cohort of STELLAR-002 trial
select
2025-05-13 (ET)
2025-05-13
18:16:31
Exelixis initiated dose-escalation stage of first human Phase 1 study of XB628
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.0
06-20Newsfilter
PinnedExelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

  • Regulatory Approval Process: The European Medicines Agency's Committee has given a positive opinion for CABOMETYX to treat adult patients with advanced neuroendocrine tumors, and the final decision from the European Commission is expected soon.

  • Clinical Trial Results: The CHMP recommendation is based on the phase 3 CABINET trial, which demonstrated superior efficacy of CABOMETYX compared to placebo in treating previously treated neuroendocrine tumors.

Preview
8.0
06-20NASDAQ.COM
First Week of EXEL February 2026 Options Trading

  • Put Contract Strategy: Investors can sell a put contract at a $40.00 strike price, collecting a premium that lowers their effective purchase price to $35.40, with a 62% chance of the contract expiring worthless, potentially yielding an 11.50% return on cash commitment.

  • Call Contract Strategy: Purchasing shares at $40.58 and selling a covered call at a $42.00 strike could yield a total return of 17.05%, with a 43% chance of the call expiring worthless, allowing investors to keep both shares and premium for a potential 13.55% extra return.

Preview
9.0
06-20SeekingAlpha
Madrigal, Ipsen, SpringWorks get EU backing for their drugs

  • EU Drug Regulator Endorsements: The European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending conditional marketing authorizations for Madrigal Pharmaceuticals' Rezdiffra, Ipsen's Cabometyx, and SpringWorks Therapeutics' Mirdametinib, with decisions expected between 2025 and 2026.

  • Treatment Focus: Rezdiffra targets noncirrhotic MASH with liver fibrosis, Cabometyx is for advanced neuroendocrine tumors, and Mirdametinib is aimed at treating symptomatic plexiform neurofibromas in patients with neurofibromatosis type 1.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Exelixis Inc (EXEL) stock price today?

The current price of EXEL is 40.37 USD — it has decreased -0.91 % in the last trading day.

arrow icon

What is Exelixis Inc (EXEL)'s business?

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

arrow icon

What is the price predicton of EXEL Stock?

Wall Street analysts forecast EXEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 42.21 USD with a low forecast of 29.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Exelixis Inc (EXEL)'s revenue for the last quarter?

Exelixis Inc revenue for the last quarter amounts to 555.45M USD, increased 30.62 % YoY.

arrow icon

What is Exelixis Inc (EXEL)'s earnings per share (EPS) for the last quarter?

Exelixis Inc. EPS for the last quarter amounts to 0.55 USD, increased 358.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Exelixis Inc (EXEL)'s fundamentals?

The market is revising Upward the revenue expectations for Exelixis, Inc. (EXEL) for FY2025, with the revenue forecasts being adjusted by 3.6% over the past three months. During the same period, the stock price has changed by 7.03%.
arrow icon

How many employees does Exelixis Inc (EXEL). have?

Exelixis Inc (EXEL) has 1147 emplpoyees as of June 23 2025.

arrow icon

What is Exelixis Inc (EXEL) market cap?

Today EXEL has the market capitalization of 11.01B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free